Your browser doesn't support javascript.
loading
Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
Miret, Jorge A; Moreno, Javier; Nieto, Javier; Carter, Katharine C; Mullen, Alexander B; Ambros, Luis; Rodríguez, Casilda; San Andrés, Manuel Ignacio; González, Fernando.
Afiliação
  • Miret JA; Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, Dr. Cecilio Báez casi Dr. Gaspar Villamayor. Campus UNA, CP 2169, San Lorenzo, Paraguay. Electronic address: jmiret@vet.una.py.
  • Moreno J; WHO Collaborating Center for Leishmaniasis, Centro Nacional Microbiología, Instituto de Salud Carlos III. Crta, Majadahonda a Pozuelo Km 2, 28220, Majadahonda, Madrid, Spain.
  • Nieto J; WHO Collaborating Center for Leishmaniasis, Centro Nacional Microbiología, Instituto de Salud Carlos III. Crta, Majadahonda a Pozuelo Km 2, 28220, Majadahonda, Madrid, Spain.
  • Carter KC; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Catedral St Glasgow G 4 ORE, Glasgow, United Kingdom.
  • Mullen AB; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Catedral St Glasgow G 4 ORE, Glasgow, United Kingdom.
  • Ambros L; Cátedra de Farmacología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires. Av. Chorroarin 280, Buenos Aires, Argentina.
  • Rodríguez C; Cátedra de Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, Avenida Puerta del Hierro s/n, Ciudad Universitaria, 28040, Madrid, Spain.
  • San Andrés MI; Cátedra de Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, Avenida Puerta del Hierro s/n, Ciudad Universitaria, 28040, Madrid, Spain.
  • González F; Cátedra de Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid, Avenida Puerta del Hierro s/n, Ciudad Universitaria, 28040, Madrid, Spain.
Exp Parasitol ; 220: 108033, 2020 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-33166530
ABSTRACT
Infection with Leishmania infantum causes the disease visceral leishmaniasis (VL), which is a serious clinical and veterinary problem. The drugs used to treat canine leishmaniasis (CanL) do not cause complete parasite clearance; they can be toxic, and emerging drug resistance in parasite populations limits their clinical utility. Therefore, in this study we have evaluated the toxicity and efficacy of joint treatment with a 11 mixture of sodium stibogluconate-NIV (SSG-NIV, 10 mg Sbv/day) and paromomycin-NIV (PMM-NIV, 10 mg PMM/kg/day), given intravenously daily for seven days from day 270 post-infection, to nine-month-old female beagle dogs (n = 6) experimentally infected with Leishmania infantum. Treatment significantly improved the clinical symptoms of VL infection in all the treated dogs, reduced parasite burdens in lymph nodes and bone marrow, and all symptomatic treated dogs, were asymptomatic at 90 days post-treatment. Treatment was associated with a progressive and significant decrease in specific IgG anti-Leishmania antibodies using parasite soluble antigen (p < 0.01) or rK39 (p < 0.01) as the target antigen. In addition, all dogs were classified as parasite negative based on Leishmania nested PCR and quantitative real time PCR tests and as well as an inability to culture of promastigote parasites from lymph nodes and bone marrow tissue samples taken at day 90 post-treatment. However, treatment did not cure the dogs as parasites were detected at 10 months post-treatment, indicating that a different dosing regimen is required to cause long term cure or prevent relapse.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Idioma: Inglês Revista: Exp Parasitol Ano de publicação: 2020 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Idioma: Inglês Revista: Exp Parasitol Ano de publicação: 2020 Tipo de documento: Artigo